ClinicalTrials.gg
RecruitingNCT07396623DEPSYSTAGEUpdated Feb 9, 2026

Validation of French PHQ-4 and PC-PTSD-5 Screening Scales

An observational study in Mental Illness, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-09.

Primary conditionStress Disorders, Post-TraumaticRegistry: Mental DisordersReclassifiedWhy we changed it
Registry
Mental Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Stress Disorders, Post-Traumatic
Why
  1. The study's title name Stress Disorders, Post-Traumatic, a narrower term within Mental Disorders.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
90
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Stress Disorders, Post-Traumatic by Assistance Publique - Hôpitaux de Paris — 7 open to participants now, 7 under way, none of them phase 3. Stress Disorders, Post-Traumatic · Assistance Publique - Hôpitaux de Paris.

Planned enrollment
7th of 10
90 · median 488
Started
2026
with 1 other
Observational
10 of 22
4 open now
Registered
22nd of 22
by date

Among the 22 studies in Stress Disorders, Post-Traumatic by Assistance Publique - Hôpitaux de Paris, this one is the 7th largest by planned enrollment of the 10 observational ones that give a count, is one of 2 that started in 2026, is one of 10 observational ones, and was the 22nd registered.

Stress Disorders, Post-Traumatic

2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

7 of the 22 studies in Stress Disorders, Post-Traumatic by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 416 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 202 (49%) stop at 75 or younger; 62 take children under 18; 88 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Stress Disorders, Post-Traumatic by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

Mental illness is a major public health issue. It affects one in five people, represents the largest expense for health insurance (14%), is the leading cause of years lived with disability, and suicide is the main cause of death among people aged 15 to 35. Depression affects 15 to 20% of individuals at some point in their lives. Trauma-related disorders affect 4.6% of people, including 1- 2% with post-traumatic stress disorder (PTSD).

Screening for mental health problems in primary care is crucial. It enables doctors to provide early treatment, reduces the need for emergency care, and decreases both the number and duration of hospital stays. However, general practitioners and other non-mental health professionals often report lacking the time, training, and tools to conduct such screenings. Fortunately, brief and validated screening tools exist in English: The PHQ-4 (Patient Health Questionnaire-4) for anxiety and depression, and the PC-PTSD-5 (Primary Care PTSD Screen for DSM-5) for PTSD. So far, no French versions of these tools have been validated.

Read the detailed description

A target of 10 patients per item of the tested scales was set. The PHQ-4 includes four items and the PC-PTSD-5 includes five items, corresponding to required sample sizes of 40 and 50 patients, respectively. Although the same patient sample completes both scales, these sample sizes were combined to account for potential loss to follow-up and to optimize statistical power, resulting in a total inclusion target of 90 patients.

Descriptive analyses of sociodemographic and clinical characteristics will be conducted for all included patients. Quantitative variables will be summarized using means and standard deviations, and qualitative variables using frequencies and percentages.

To address the primary objective, convergent validity will be assessed using Pearson's correlation coefficients between scores obtained on the tested scales (PHQ-4 and PC-PTSD-5) and those obtained on their respective gold standard instruments (PHQ-9, GAD-7, and PCL-5). Convergent validity will also be examined by inclusion center through comparison of correlation coefficients across centers.

Secondary objectives will be addressed through:

  • Exploratory factor analysis to examine the dimensional structure of each scale and to compare it with that of the corresponding gold standard.
  • Assessment of internal consistency using Cronbach's alpha coefficient. Test-retest reliability will be evaluated using the intraclass correlation coefficient on a subsample of at least 20 participants, depending on the final total sample size, who will complete the PHQ-4 and PC-PTSD-5 scales twice.
  • Evaluation of diagnostic performance by calculating sensitivity and specificity for each scale among patients undergoing a psychiatric diagnostic assessment, with receiver operating characteristic (ROC) curves generated for each scale.
  • Assessment of feasibility based on the time required to complete both scales.

All statistical tests will be two-sided and considered statistically significant at an alpha level of 0.05.

No statistical imputation methods will be used for the management of missing data.

03

Conditions studied

  • Mental Illness

Keywords

  • Post-Traumatic Stress Disorder
  • Depression
  • Anxiety
  • Screening tool
04

In context

Stress Disorders, Post-Traumatic Reclassified

2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.

This study's planned enrollment of 90 is below the median of 150 across 371 observational studies indexed under Stress Disorders, Post-Traumatic.

Browse Stress Disorders, Post-Traumatic studies →

Lead sponsor

Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.

Compared within Stress Disorders, Post-Traumatic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Mental Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This study will involve adult patients, regardless of sex, who present for consultation.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years,
  • Outpatient or hospitalized for any health-related reason,
  • Oral and written proficiency in French,
  • Patient informed and willing to participate in the study,
  • Patient with health insurance coverage

Exclusion criteria

Exclusion Criteria:

  • Individuals under legal protection measures (guardianship, conservatorship, or legal supervision),
  • Other factors preventing obtaining non-opposition or conducting the research, such as: limited French proficiency, hearing impairment, or significant cognitive disorders
06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
90 participants (estimated)
Target follow-up
554 Days
Patient registry
Yes
07

What researchers measure

Primary outcomes

  1. Assess the validity of the French version of the PHQ-4 (Patient Health Questionnaire-4 ) scale

    This scale is used for the screening of anxiety and depression. The scale will be scored. Score ranging from 0 to 12, corresponding to four levels of psychological distress: * None: 0-2 * Mild: 3-5 * Moderate: 6-8 * Severe: 9-12 Patients will complete this scale at Visit 1 and Visit 2.

    Time frame: 14 days

  2. Assess the validity of the French version of the PC-TDSD-5 (Primary Care PTSD Screen for DSM-5) scale

    Scale assessing whether the patient has experienced unusually or particularly frightening, horrible, or traumatic events. Examples include: * A serious accident or fire * Physical or sexual assault, or sexual abuse * An earthquake or flood * War * Witnessing a person being killed or seriously injured * The death of a close person by homicide or suicide Total score = sum of "YES" responses to questions 1 through 5. Patients will complete this scale at Visit 1 and Visit 2.

    Time frame: 14 days

Secondary outcomes

  1. Assess the feasibility of this screening tool during the first evaluation visit.

    The time required for the patient to complete each scale (individually) will be timed and recorded (without informing the patient in order to avoid potential stress).

    Time frame: At Visit 1 (at inclusion)

08

Study locations

1 of 1 sites recruiting
  • Hôpital Avicenne
    Bobigny, 93000, France
    Recruiting
    • Vladimir ADRIEN, Doctor · Contactvladimir.adrien@aphp.fr · +33148955421
    • Gaelle Colevray · Contactgaellecolevray@gmail.com
    • Vladimir Adrien, Doctor · Principal investigator
    • Nicolas Vignier, Professor · Principal investigator
    • Gaëlle Colevray, Medical student · Principal investigator
    • Anne Mottais, Doctor · Principal investigator
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Aug 2027, 18 months after the start.

Of 142 non-industry observational studies under Stress Disorders, Post-Traumatic, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 54. This study's planned 18 months is below that.

Counting every sponsor, half of 149 studies reached it within 34 months; a quarter within 14 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2026
First posted
Feb 9, 2026
StartActual
Jan 26, 2026
Primary completionEst.
Aug 15, 2027
CompletionEst.
Aug 15, 2027
Last update
Feb 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07396623
Responsible party
Sponsor
First posted
Feb 9, 2026
Start date
Jan 26, 2026
Primary completion
Aug 15, 2027 (estimated)
Completion
Aug 15, 2027 (estimated)
Last update
Feb 9, 2026

Study contacts

Vladimir ADRIEN, Doctor
Contact
vladimir.adrien@aphp.fr
(+33) 1 48 95 59 37

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion